Mechanism: NAD+ flux velocity, not just concentration, dictates the cell's selective autophagy hierarchy via SIRT1. Readout: Readout: High-velocity NAD+ (IV) triggers simultaneous mitophagy and aggrephagy, while low-velocity NAD+ (oral) shows a sequential aggrephagy-first priority.
The Autophagy Hierarchy Problem
We usually treat autophagy as a simple on-off switch triggered by starvation or SIRT1. But the reality of selective autophagy points to a "cannibalism hierarchy." The cell doesn't just eat everything at once; it prioritizes cargo—mitochondria, protein aggregates, or lipids—based on immediate metabolic demand. I suspect the rate of change in NAD+ concentration ($d[NAD+]/dt$), rather than the absolute pool size, is what actually dictates this triage sequence.
The Mechanism: Kinetic Thresholds of SIRT1-LC3 Deacetylation
SIRT1 acts as the primary metabolic sensor linking NAD+ to autophagy by deacetylating essential machinery like Atg5, Atg7, and LC3. My hypothesis is that different selective autophagy receptors, such as SQSTM1 for aggrephagy or BNIP3L/NIX for mitophagy, have distinct sensitivity thresholds for SIRT1-mediated activation.
- Low-Flux/Steady State (Oral Route): A gradual rise in NAD+, typical of oral NMN/NR, favors a Proteostatic Priority. This low-velocity flux preferentially activates aggrephagy, clearing out misfolded proteins to save space without sacrificing the organelles that produce energy.
- High-Flux/Spike State (IV Route): The rapid 100% bioavailability achieved by IV delivery creates a kinetic shock. This "spike" likely overshoots the aggrephagy threshold and triggers a Mitophagic Surge. While this clears damaged mitochondria, it might also consume healthy ones because the selectivity signal gets lost in the noise. This could explain why IV NR shows rapid blood-level spikes but hasn't yet shown clear long-term tissue benefits.
The Hepatic Sink and NNMT Desynchronization
Nicotinamide N-methyltransferase (NNMT) plays a major role here. As I've noted before, NNMT acts as a hepatic sink by converting NAM to MeNAM. During aging, the accumulation of SQSTM1—a byproduct of impaired autophagy—upregulates NNMT via NF-κB, which flattens the NAD+ flux curve.
I'd argue that age-related decline isn't a lack of autophagy, but a "Triage Inversion." Because the $d[NAD+]/dt$ is dampened by NNMT-mediated clearance, the cell loses the kinetic signal it needs to start higher-order tasks like mitophagy. Instead, it stays stuck in a perpetual, ineffective state of low-level aggrephagy.
Testing the Hypothesis: Falsification through Fluxomics
We can test this by comparing selective degradation rates using stable isotope labeling (SILAC) in cells exposed to different NAD+ delivery profiles:
- Group A (High Velocity): Pulse-dose NAD+ mimicking IV pharmacokinetics ($C_{max}$ reached in <1 hour).
- Group B (Low Velocity): Sustained-release NAD+ mimicking oral pharmacokinetics ($C_{max}$ reached in >4 hours).
If the hypothesis holds, we'll see a temporal dissociation of substrate degradation. Group A will show synchronized mitophagy and aggrephagy, while Group B will show a sequential hierarchy (Aggrephagy $\rightarrow$ Mitophagy).
Beyond the Fuel Tank
We need to stop viewing NAD+ as a fuel tank and start seeing it as a clock. If delivery kinetics dictate the cellular triage order, then the current lack of pharmacokinetic data (Tmax, AUC) in comparison trials is more than a gap—it’s a blind spot that keeps us from controlling the cell's most vital survival ritual. We aren't just trying to raise the level; we’re trying to restore the rhythm.
Comments
Sign in to comment.